CELL INTELLIGENCE · 肿瘤细胞治疗研究

浆细胞疾病细胞免疫治疗的 2025 年更新

2025 Update of Cellular Immunotherapy for Plasma Cell Disorders.

CAR-T 与 CAR NK 细胞的在靶脱瘤效应差异提示细胞治疗的疗效与安全性不同

Divergent on-target off-tumor effects by CAR T and CAR NK cells suggest different efficacy and safety of cell therapies.

超越 CAR-T：CAR-NK/T 细胞在血液肿瘤中的兴起

Beyond CAR-T: The Rise of CAR-NK/T Cells for Haematological Cancer.

CAR-NK/T 细胞可能被证明是治疗血液系统恶性肿瘤的一种更安全、更灵活的细胞疗法。

过继性细胞免疫治疗进展及多发性骨髓瘤治疗突破

Advances in adoptive cellular immunotherapy and therapeutic breakthroughs in multiple myeloma.

CXCR4 在提高多发性骨髓瘤中 BCMA 重定向 CAR-NK 细胞疗效中的双重作用

CXCR4 has a dual role in improving the efficacy of BCMA-redirected CAR-NK cells in multiple myeloma.

表达抗 BCMA CAR 及分泌型 TRAIL 的 NK92 治疗多发性骨髓瘤：初步体外评估

NK92 Expressing Anti-BCMA CAR and Secreted TRAIL for the Treatment of Multiple Myeloma: Preliminary In Vitro Assessment.

CD44v6 特异性 CAR-NK 细胞用于头颈部鳞状细胞癌的靶向免疫治疗

CD44v6 specific CAR-NK cells for targeted immunotherapy of head and neck squamous cell carcinoma.

mRNA-LNP 制备的 CAR-NK 细胞在体外和体内杀伤肿瘤靶细胞

CAR-NK Cells Generated with mRNA-LNPs Kill Tumor Target Cells In Vitro and In Vivo.

αCD38 嵌合抗原受体（CAR）表达自然杀伤（NK）细胞免疫治疗多发性骨髓瘤的挑战：利用细胞因子刺激 NK 细胞的 CD38dim 表型作为防止自相残杀的策略

Challenges in αCD38-chimeric antigen receptor (CAR)-expressing natural killer (NK) cell-based immunotherapy in multiple myeloma: Harnessing the CD38di

我们的结果强调，将功能性 CD38-CAR 构建体纳入合适的 NK 细胞扩增与激活方案，可形成一种强效且可行的免疫治疗策略，用于治疗 MM 患者。

表达亲和力优化 CD38 嵌合抗原受体的 CD38 敲除 NK 细胞成功靶向急性髓系白血病并减少效应细胞自相残杀

CD38 knockout natural killer cells expressing an affinity optimized CD38 chimeric antigen receptor successfully target acute myeloid leukemia with red